Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Zylox-Tonbridge Medical Technology Co., Ltd.
歸創通橋醫療科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2190)

FURTHER INFORMATION IN RELATION TO THE ACQUISITION OF 49% EQUITY INTERESTS IN THE TARGET COMPANY

Reference is made to the announcement (the "**Announcement**") of Zylox-Tonbridge Medical Technology Co., Ltd. (the "**Company**") dated January 16, 2026 in relation to the acquisition of 49% equity interests in the Target Company. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement. The Company hereby provides the following further information supplementing the disclosure regarding the growth potential and future prospects of the Target Company and the Board's assessment thereof.

The Target Group is principally engaged in the development, manufacturing and distribution of medical technology products, instruments and solutions. As an innovative medical device company, the profitability of the Target Group is not the sole indicator of its growth and future potential. The Board has considered the following factors in assessing the potential of the Target Group and the benefits of the Acquisition to the Group:

(i) **Continued commitment to research and development ("R&D") efforts and advancement of manufacturing capabilities, which is fundamental for future growth:** The Target Group has incurred losses in recent years, primarily attributable to its substantial costs in (i) the transition and expansion of its manufacturing facilities; (ii) research and development of key products; and (iii) increased costs regarding the mandatory regulatory transition of all medical device products in the European market required to sustain and expand market access. Based on information available to the Company, since 2023 the Target Group has been undertaking the transition from the Medical Device Directive ("**MDD**") to the Medical Devices Regulation ("**MDR**"), a mandatory regulatory transition applicable to all medical device products in the European market. This transition has resulted in additional costs, including external services, product testing and sample manufacturing. By the end of 2025, the Target Group had completed regulatory filings for approximately 70% of its products

under the MDR framework in Europe, with the majority of external costs and testing expenses having been recognized in the past two financial years. The Company expects to complete the regulatory filings (the "**Remaining Regulatory Filings**") for the remaining key products by the end of 2027 at an aggregate cost of approximately EUR2 million. As the remaining key products are available for sale until the end of 2027 (i.e. before completion of the Remaining Regulatory Filings), the Board is of the view that the Remaining Regulatory Filings will not have a material impact on the Group's financial indicators and are in the interest of the Company and its shareholders as a whole.

The Company believes these R&D and capital investments are essential and would enable the Target Group to continue the commercialization of its existing products and to lay the foundation for its future growth. The success of the Target Group in its continued R&D achievements and commercialization of product offering is a testament to the Target Group's growth potential.

(ii) **Advance Market Positioning and Product Portfolio:** Within the Target Group, Optimed has been dedicated to the research, development, manufacturing and global distribution of high-quality medical products for minimally invasive vascular and endourology procedures for many years. The Target Group has one of the most comprehensive product portfolios in the peripheral venous stenting market, including specialized devices for the iliofemoral veins, iliac bifurcation, vena cava and aorta. The Target Group's brand is also highly reputable in the market considering the product quality and the high-end positioning.

The Company believes that such comprehensive product offerings and brand, coupled with the significant growing trends in minimally invasive therapy driven by multiple factors (including, without limitation, the overall technological advancement enhancing surgical precision and complex procedures, aging population and rising prevalence of chronic diseases, and a growing preference for minimally invasive interventions), underpin the Target Group's medium-to long-term growth potential.

(iii) **Potential Collaboration and Distribution for the Group:** As disclosed in the paragraph headed "Strategic Collaboration" in the Announcement, upon completion of the Acquisition, it is expected that the Target Company will serve as the Company's combined distribution platform for all vascular products in markets outside mainland China. The Company believes that the Target Company's role as the Group's overseas vascular products platform will enhance the utilization and effectiveness of the existing sales network and customer relationships from the Company and the Target Group, thereby supporting its financial trajectory.

The Board is of the view that the Acquisition is in the interests of the Company and its shareholders as a whole, having considered the following factors:

(i) **Strategic value signified by the Acquisition and synergies with the Group:** As disclosed in the Announcement, the Acquisition signifies a milestone in the Group's long-term commitment to the global expansion. Following completion of the Acquisition, the Target Company will distribute all vascular products in markets outside mainland China.

It is expected that the Target Group will provide the Group with an established overseas platform in the minimally invasive vascular and endourology fields and an international distribution network, which would be costly and time-consuming for the Group to develop organically. The combined strength of the Group's and Optimed's sales networks will set to fast-track the Group's expansion of its footprint beyond mainland China, and will enable the Group to further enhance its distribution network and customer outreach and to support the Group's international growth over time.

The Board believes that the Acquisition will deliver significant manufacturing and operational synergies between Germany and China. By integrating advanced production capabilities, the Group will continuously enhance its overall product quality and operational efficiency and will continue to capitalize on the Target Company's strong European brand recognition while strategically expanding its production capacity in Germany to ensure a robust, reliable and efficient supply to European and other key international markets.

(ii) **Future Potentials of the Target Group and the Nature of Historical Losses:** As discussed in the responses above, based on information available to the Company, the Board understands that the Target Group's losses incurred in the recent financial years mainly reflected its R&D and capital investments, including (i) the transition and expansion of manufacturing facilities, (ii) increased R&D expenditure on key products and enhancements, and (iii) additional regulatory-related expenses to sustain and expand market access. The Target Group has maintained a relatively stable revenue scale over the past years. While a significant portion of R&D expenditure being expensed as incurred had depressed the Target Company's short-term profitability, it is believed that the relevant R&D and capital investments would support its future development. The Board does not consider these historical losses were indicative of a fundamental weakness in the Target Group's underlying business.

As discussed above, Optimed has been dedicated to the research, development, manufacturing and global distribution of high-quality medical products for minimally invasive vascular and endourology procedures, and the Board believes that its comprehensive product offerings, coupled with the significant growing trends in minimally invasive therapy driven by multiple factors, demonstrate the business prospects of the Target Group.

(iii) Consideration and Adjustment Mechanism: In assessing the terms of the Acquisition, the Board has taken into account the Target Group's financial position, asset base and growth potential. The consideration adjustment mechanism based on completion accounts and adjustments to reflect actual cash, financial debt and net working capital position provides downside protection to the Group in light of the Target Group's historical losses and better aligns the interests of the parties.

By order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, February 13, 2026

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Ms. Yun Qiu and Dr. Xiang Qian as independent non-executive Directors.